拉帕替尼在乳腺癌中的应用及其耐药机制研究现状

doi:10.11904/j.issn.1002-3070.2015.04.020

摘要/Abstract

摘要： 随着分子肿瘤学的发展,乳腺癌进入了分子分型时代。基于患者不同生物标志物表达的个体化医疗已经成为目前乳腺癌治疗的模式。HER2阳性乳腺癌侵袭性高、预后差,占所有乳腺癌患者的20%~30%。曲妥珠单抗作为第一个人源化单克隆抗体,以HER2为靶点,改善了这部分患者的预后,因此乳腺癌相关各大临床实践指南和专家共识明确推荐HER2阳性乳腺癌患者不同阶段均可以使用曲妥珠单抗进行抗HER2治疗。但是曲妥珠单抗的心脏毒性及原发、继发耐药等问题迫使临床医生对二线抗HER2治疗进行探索。拉帕替尼作为第一个被批准用于临床作用于HER1和HER2双靶点的酪氨酸激酶抑制剂,是曲妥珠单抗失败后的不错选择。本文对拉帕替尼在乳腺癌中的应用、相关临床研究及其耐药机制研究进行简要综述。

关键词: 乳腺肿瘤, 受体, 表皮生长因子, 拉帕替尼

Abstract: With development of molecular biology,breast cancer has entered an era of molecular classification,thus making biomarker based personalized medicine is the trend of breast cancer treatment.HER2-positive breast cancer of high invasiveness and bad prognosis accounts for 20%~30%.Targeting HER2,trastuzumab is the first humanized monoclonal antibody which can improve the prognosis of HER2-positive patients and it is recommended by guidelines and expert consensus at home and abroad for anti-HER2 therapy in any stage.However,the cardiotoxicity,de novo resistance and acquired resistance of trastuzumab make the clinician to explore the second line anti-HER2 therapy.Lapatinib is the first FDA approved and HER1,HER2 double-targeting tyrosine kinase inhibitor which can be a better choice after failure with trastuzumab.This article reviews the application,some clinical and mechanism of drug resistance researches of Lapatinib.

Key words: Breast neoplasms, Receptor, Epidermal growth factor, Lapatinib

中图分类号:

R737.9

杜歌,江泽飞. 拉帕替尼在乳腺癌中的应用及其耐药机制研究现状[J]. 实用肿瘤学杂志, 2015, 29(4): 376-379.

DU Ge,JIANG Zefei. The application of Lapatinib in breast cancer and its mechanism of drug resistance[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 376-379.

参考文献

1 Gradishar WJ,Anderson BO,Blair SL,et al.Breast cancer version 3.2014[J].J Natl Compr Canc Netw,2014,12(4):542-590.
2 Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
3 宋金洁,王涛,边莉,等.曲妥珠单抗联合蒽环类药物应用于Her-2阳性乳腺癌的新辅助治疗初步临床研究[J].实用肿瘤学杂志,2013,27(2):97-100.
4 Bian L,Wang T,Zhang S,et al.Trastuzumab plus capecitabine vs.lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer[J].Tumor Biol,2013,34(5):3153-3158.
5 Hynes NE,Lane HA.ERBB receptors and cancer:the complexity of targeted inhibitors[J].Nat Rev Cancer,2005,5(5):341-354.
6 Hegde PS,Rusnak D,Bertiaux M,et al.Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles[J].Mol Cancer Ther,2007,6(5):1629-1640.
7 Rusnak DW,Lackey K,Affleck K,et al.The effects of the novel,reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor,GW2016,on the growth of human normal and tumor-derived cell lines in vitro and in vivo[J].Mol Cancer Ther,2001,1(2):85-94.
8 Bence AK,Anderson EB,Halepota MA,et al.Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016,a dual EGFR-ErbB2 inhibitor,in healthy subjects[J].Invest New Drug,2005,23(1):39-49.
9 Burris HA,Hurwitz HI,Dees EC,et al.Phase I safety,pharmacokinetics,and clinical activity study of lapatinib(GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
10 Burstein HJ,Storniolo AM,Franco S,et al.A phase II study of lapatinibmonotherapy in chemotherpy-refractory HER2-positive and HER2-negativeadvancedmetastatic breast cancer[J].Ann Oncol,2008,19(6):1068-1074.
11 Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].N Engl J Med,2006,355(26):2733-2743.
12 Di Leo A,Gomez HL,Aziz Z,et al.Phase III,double-blind,randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer[J].J Clin Oncol,2008,26(34):5544-5552.
13 Johnston S,Pippen J,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
14 Bachelot T,Romieu G,Campone M,et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer(LANDSCAPE):a single-group phase 2 study[J].Lancet Oncol,2013,14(1):64-71.
15 Goss PE,Smith IE,O′Shaughnessy J,et al.Adjuvant lapatinib for women with early-stage HER2-positive breast cancer:a randomised,controlled,phase 3 trial[J].Lancet Oncol,2013,14(1):88-96.
16 Baselga J,Bradbury I,Eidtmann H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2012,379(9816):633-640.
17 Robidoux A,Tang G,Rastogi P,et al.Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer(NSABP protocol B-41):an open-label,randomized phase 3 trial[J].Lancet Oncol,2013,14(12):1183-1192.
18 Guarneri V,Frassoldati A,Bottini A,et al.Preoperative chemotherapy plus trastuzumab,lapatinib,or both in human epidermal growth factor receptor2-positive operable breast cancer:results of therandomizedphase II CHER-LOB study[J].J Clin Oncol,2012,30(16):1989-1995.
19 Eichhorn PJ,Gili M,Scaltriti M,et al.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235[J].Cancer Res,2008,68(22):9221-9230.
20 Junttila TT,Akita RW,Parsons K,et al.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941[J].Cancer Cell,2009,15(5):429-440.
21 O′Brien NA,Browne BC,Chow L,et al.Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib[J].Mol Cancer Ther,2010,9(6):1489-1502.
22 Zoppoli G,Moran E,Soncini D,et al.Ras-induced resistance to lapatinib is overcome by MEK inhibition[J].Curr Cancer Drug Tar,2010,10(2):168-175.
23 Xia W,Bacus S,Hegde P,et al.A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer[J].P Natl Acad Sci,2006,103(20):7795-7800.
24 Baselga J,Bradbury I,Eidtmann H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2012,379(9816):633-640.
25 McDonagh CF,Huhalov A,Harms BD,et al.Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3[J].Mol Cancerther,2012,11(3):582-593.
26 Liu L,Greger J,Shi H,et al.Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells:activation of AXL[J].Cancer Res,2009,69(17):6871-6878.
27 周金妹,江泽飞.液体肿瘤生物指标检测对乳腺癌患者的价值[J].中国癌症杂志,2014,24(8):636-640.

[1]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.
[2]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[3]	韩帮岭, 汪亦民综述, 薛英威审校. 维生素D在消化系统肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 471-475.
[4]	姜涛, 张旭. 孤儿核受体在前列腺癌中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 377-380.
[5]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.
[6]	王笑笑, 华腾, 汪宏波. 雌激素受体相关受体γ在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 87-91.
[7]	唐小崧综述，陈公琰审校. 受体酪氨酸激酶AXL在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(3): 281-284.
[8]	汤大北, 金艳, 龚振琴, 初众, 曹仲茹, 张清媛. 三阴性乳腺癌中miRNA-124表达与E-钙黏蛋白及雄激素受体的关系[J]. 实用肿瘤学杂志, 2017, 31(2): 97-101.
[9]	于飞, 胡晶(综述), 陈雪松(审校). 乳腺癌他莫昔芬耐药机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 160-164.
[10]	王婷综述,陈雪松审校. 肾素-血管紧张素系统相关受体在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(4): 365-369.
[11]	汪霖综述, 孟祥宁审校. 人类表皮生长因子受体2阳性肿瘤靶向药物研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 266-270.
[12]	刘伟综述, 李惠艳审校. 表皮生长因子受体与放射敏感性关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 275-278.
[13]	张锐, 王智煜, 文孝婷综述, 赵晖审校. 肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 167-171.
[14]	李欢, 井明晰, 孙涛. 血脂与激素受体阴性乳腺癌远处转移及疗效的关系[J]. 实用肿瘤学杂志, 2015, 29(5): 432-437.
[15]	郑国良, 郑志超, 赵岩, 张涛, 张剑军. 胃癌HER-2表达的临床意义及血管新生相关性研究[J]. 实用肿瘤学杂志, 2015, 29(5): 438-443.